两例转移性割抵抗性前列腺癌的病例,长期存活,用阿比拉特龙治疗
Minami Une1, Shinya Yamamoto1, Honoka Fuse1
1Department of Urology Nishitokyo Chuo General Hospital Tokyo Japan.
Clinical case reports
|December 8, 2025
概括
两名转移性割抵抗性前列腺癌 (mCRPC) 患者在阿比拉治疗后实现了超过五年的长期生存. 这表明abiraterone可能在选择的mCRPC病例中提供持久的反应.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 是前列腺癌的晚期阶段.
- 阿比拉是对mCRPC的常见治疗方法,但它的疗效往往是暂时的.
研究的目的:
- 报告mCRPC患者治疗abiraterone的长期存活情况.
- 调查mCRPC中对阿比拉的持续反应的可能性.
主要方法:
- 两名mCRPC患者的病例报告.
- 用abiraterone进行治疗.
主要成果:
- 这两位患者在5年多的时间里都没有出现病变的进展.
- 在阿比拉治疗后实现了长期生存.
结论:
- 在一些mCRPC患者中,阿比拉可以导致持久的反应.
- 在特定的mCRPC病例中,使用abiraterone可以实现长期存活.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630


